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Abstract
Introduction:  Several  theories  attempt  to  explain  the  pathophysiology  of  sudden  hearing  loss.
Objective:  The  objective  of  this  study  was  to  investigate  the  possible  role  of  inﬂammation  and
atherothrombosis  in  sudden  hearing  loss  patients  through  the  neutrophil-to-lymphocyte  ratio
and mean  platelet  volume.
Methods:  Study  design  --  retrospective  cross-sectional  historical  cohort.  This  study  was  con-
ducted on  two  groups:  one  with  59  individuals  diagnosed  with  sudden  hearing  loss,  and  other
with 59  healthy  individuals  with  the  same  characteristics  of  gender  and  age  distribution,
neutrophil-to-lymphocyte  ratio  and  mean  platelet  volume  levels  were  measured  in  patients
diagnosed  with  sudden  hearing  loss  as  well  as  in  the  control  group,  and  it  was  veriﬁed  whether
these results  interfered  for  a  better  or  worse  prognosis  with  treatment  of  sudden  deafness.
Results:  Neutrophil-to-lymphocyte  ratio  levels  are  much  higher  in  patients  diagnosed  with
sudden hearing  loss  compared  to  the  control  group.  Similarly,  mean  levels  of  neutrophil-to-
lymphocyte  ratio  are  higher  in  non-recovered  versus  recovered  patients  (p  =  0.001).  However,
we could  not  ﬁnd  a  correlation  with  mean  platelet  volume  levels  (p  >  0.05).
Conclusion:  Neutrophil-to-lymphocyte  ratio  is  a  quick  and  reliable  indicator  regarding  diagno-
sis and  prognosis  of  sudden  hearing  loss;  on  the  other  hand,  mean  platelet  volume  may  be
considered  a  less  important  indicator  in  this  aspect.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published  by
Elsevier Editora  Ltda.  All  rights  reserved.
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Resumo
Introduc¸ão:  Várias  teorias  tentam  explicar  a  ﬁsiopatologia  da  surdez  súbita  (SS).
Objetivo:  :  O  objetivo  deste  estudo  foi  investigar  o  possível  papel  da  inﬂamac¸ão  e  da  aterotrom-
bose nos  pacientes  de  SS  através  da  relac¸ão  neutróﬁlos/linfócitos  (RNL)  e  volume  plaquetário
médio (VPM).
Método:  Forma  de  estudo  --  coorte  histórica  com  corte  transversal  (retrospectivo).  Este  estudo
foi realizado  com  59  indivíduos  portadores  de  SS  e  59  saudáveis,  com  as  mesmas  característi-
cas em  distribuic¸ão  de  gênero  e  idade.  Os  níveis  de  VPM  e  RNL  foram  medidos  nos  pacientes
diagnosticados  com  SS  e  no  grupo  controle,  veriﬁcando-se  se  tais  resultados  implicavam  em  um
melhor ou  pior  prognóstico  com  o  tratamento  da  surdez  súbita.
Resultados:  Os  níveis  da  RNL  são  muito  mais  altos  em  pacientes  com  SS,  em  comparac¸ão  com
o grupo  controle.  De  forma  semelhante,  níveis  médios  da  RNL  são  mais  altos  nos  pacientes  não
recuperados,  em  comparac¸ão  com  os  recuperados  (p  =  0,001).  Essas  diferenc¸as  entretanto,  não
foram observadas  em  relac¸ão  aos  níveis  de  VPM  (p  >  0,05).
Conclusão:  RNL  é  um  indicador  rápido  e  conﬁável  no  que  diz  respeito  ao  diagnóstico  e  prognós-
tico de  SS;  por  outro  lado,  VPM  pode  ser  um  indicador  menos  importante  neste  aspecto.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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Sudden  hearing  loss  (SHL)  is  a  disease  characterized  by  a
loss  of  hearing  greater  than  30  dB  in  three  contiguous  fre-
quencies  that  occurs  in  less  than  three  days.1 The  incidence
of  SHL  ranges  from  5  to  20  cases  per  100,000  individuals.2,3
Since  the  physiopathology  of  SHL  is  still  unclear,  there  are
many  theories  as  to  the  origin  of  this  disease,  including
bacterial,  viral  and  protozoal  infections,  blood  disorders,
vascular  occlusion,  immune  disorders,  ototoxic  drugs,  and
metabolic  conditions.3--7
The  cochlea  is  very  susceptible  to  any  alteration  of  blood-
stream.  Vascular  diseases  and  platelet  alterations  may  cause
some  cochlear  injuries  and  be  related  to  SHL.8
Platelets  secrete  and  express  a  large  number  of
substances  that  are  crucial  mediators  of  coagulation,  inﬂam-
mation,  thrombosis,  and  atherosclerosis.9 The  size  and
functional  activity  of  circulating  platelets  vary.  Larger
platelets  are  often  younger,  more  reactive,  and  produce
more  thrombogenic  factors.  Mean  platelet  volume  (MPV),
which  is  an  indicator  of  platelet  activation,  is  also  used
as  a  marker  of  atherothrombosis,10 and  may  be  an  impor-
tant  prophylactic  and  diagnostic  tool  in  thrombotic  and
prothrombotic  cases.
White  blood  cell  (WBC)  count  is  a  useful  inﬂammatory
biomarker  in  clinical  practice.  Even  if  the  WBC  is  within
a  normal  range,  subtypes  of  WBC,  such  as  neutrophil-
to-lymphocyte  ratio  (NLR),  may  predict  cardiovascular
mortality.11,12 NLR  is  an  easily  measurable  laboratory
marker  that  is  used  to  evaluate  systemic  inﬂammation  and
it  has  also  superiority  compared  to  other  WBC  subtype
counts  (e.g.,  neutrophil,  lymphocyte,  and  total  leukocyte
counts).  This  superiority  may  be  due  to  the  stability  of
NLR  compared  to  the  other  WBC  subtype  counts,  which
could  be  affected  by  various  pathological  and  physiological
c
t
ionditions. As  these  factors  can  alter  the  individual  WBC
ubtype  counts,  NLR  may  remain  more  stable.  Moreover,
LR  may  represent  both  inﬂammatory  and  immune  path-
ays  that  exist  together  in  the  patients.  NLR  has  been
eﬁned  as  a  novel  and  potential  marker  to  determine
nﬂammation  in  cardiac  and  non-cardiac  disorders.11,13--18
Recently,  the  relationship  between  MPV  and  NLR  with
HL  were  investigated  individually.15,19--21 However,  to  the
uthors’  knowledge,  this  is  the  ﬁrst  study  evaluating  MPV
nd  NLR  together,  and  in  comparison  with  each  other,  in  the
iagnosis  and  prognosis  of  the  SHL  patients.  Since  NLR  is  an
ndicator  of  inﬂammation  and  MPV  indicates  atherothrom-
osis,  this  study  aimed  to  contribute  to  the  literature  by
nvestigating  the  role  of  inﬂammation  and  atherothrombosis
n  SHL  patients  by  using  NLR  and  MPV,  respectively.
ethods
his  cross-sectional  historical  cohort  study  included  an  SHL
atient  group  and  a healthy  control  group.  The  SHL  group
ncluded  59  patients  who  were  admitted  to  a  tertiary  refer-
al  hospital  ENT  Clinic  and  were  diagnosed  with  SHL  between
ay  of  2010  and  December  of  2013.  Patients  with  his-
ory  or  clinical  ﬁndings  of  any  inﬂammatory,  autoimmune,
cute  or  chronic  infectious  diseases,  hypertension,  conduc-
ive  hearing  loss,  angina  pectoris,  myocardial  infarction,
iabetes  mellitus,  metabolic  syndrome,  chronic  obstructive
ulmonary  disease,  amyloidosis,  chronic  renal  insufﬁciency
bstructive  sleep  apnea,  current  smoking,  or  active  oto-
ogic  disease  were  excluded,  as  were  those  who  did  not
ave  a  type  A  audiometric  tympanogram.  The  control  group
ncluded  59  age-  and  sex-matched  healthy  individuals  who
ame  to  the  ENT  polyclinic  for  a  required  examination  due
o  an  employment  application,  had  normal  audiological  ﬁnd-
ngs  and  no  active  symptoms.
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NLR  was  calculated  as  a  simple  ratio  between  the  abso-
ute  neutrophil  and  the  absolute  lymphocyte  counts.  The
eckman  Coulter  LH  750  automated  blood  cell  counter
Beckman  Coulter  analyzer,  CA,  United  States)  was  used
or  complete  blood  count  (CBC)  measurements  (Neutrophil,
ymphocyte,  platelet,  NLR,  MPV  and  WBC),  which  based  on
echnique  of  laser  ﬂow  cytometry  scattergrams,  and  were
erformed  within  2  h  after  blood  sampling.  Blood  samples
rom  the  patient  group  were  obtained  before  the  patient
as  administered  any  treatment.  All  samples  were  run  in
uplicate,  and  the  mean  values  were  used  for  statistical
nalysis.
Audiometric  examinations  were  performed  in  quiet
ooms  with  an  Interacoustics  AC-40  clinical  audiometer
ccording  to  the  manufacturer  instructions,  and  all  the  tests
ere  conducted  by  the  same  audiometrist.  Audiologic  data
ere  reported  in  accordance  with  the  recommended  meth-
ds  of  the  Hearing  Committee  of  the  American  Academy  of
tolaryngology,  Head,  and  Neck  Surgery,  which  endorsed
 new  minimal  standard  for  reporting  hearing  results  in
linical  trials.22 Audiometric  examinations  were  performed
nitially  and  after  one  month  of  the  treatment.  SHL  patients
ad  a  minimum  of  30  dB  hearing  loss  at  three  consecutive
requencies  that  developed  within  72  h  and  was  not  asso-
iated  with  other  known  pathologies,  including  Meniere’s
isease,  autoimmune  disease,  ototoxicity,  or  neoplasm.  The
earing  loss  was  unilateral  in  all  patients.
All  of  the  patients  were  treated  with  the  standard  SHL
rotocol,  which  included  prednisone  in  the  dose  of  1  mg/kg
er  day,  with  a  progressive  dose  reduction,  maintained  for
t  least  two  weeks.  The  mean  interval  of  the  blood  tests
ollowing  the  onset  of  SHL  was  1.98  ±  1.26  days  (range  1--6
ays)
Patients  were  classiﬁed  as  follows  (according  to  the
ecovery  observed  in  one  month  of  follow-up):  1  --  Complete:
ure  tone  average  (PTA)  within  10  dB  hearing  levels  (HL)  of
nitial  HL  or  within  10  dB  HL  of  the  HL  of  the  unaffected  ear; --  Partial:  PTA  dB  HL  within  50%  of  initial  HL  or  greater
han  10  dB  HL  improvement  of  the  HL;  and  3  --  no  recovery:
ess  than  10  dB  HL  improvement  in  HL  relative  to  the  initial
L  1.  Then,  the  patients  were  divided  into  two  groups  as
d
m
1
s
Table  1  Intergroup  comparison  of  age,  gender,  mean  platelet  vol
platelet counts  of  the  patients  and  the  control  group.
Variables  Patient  (n  =  59)
Mean  ±  SD
Age  (years)  46.10  ±  11.91  
Gender 
Female 21  (35.6%)  
Male 38  (64.4%)  
NLR 3.24  ±  2.26  
MPV  (fL)  9.83  ±  1.50  
Platelet (103  U)  249.44  ±  48.16  
WBC (103  U)  8.39  ±  2.83  
Neutrophil  (103  U)  5.64  ±  2.55  
Lymphocyte  (103  U)  2.06  ±  0.77  
SD, standard deviation; WBC, white blood cell.
a p < 0.05.Kum  RO  et  al.
ecovered  (Complete  +  Partial)  and  unrecovered  (No  recov-
ry).  The  patients  were  also  divided  into  three  subgroups
ccording  to  severity  of  hearing  loss  as  mild  (<40  dB  loss  for
ny  frequency),  moderate  (up  to  80  dB),  and  severe  (>80  dB).
Age,  gender,  MPV,  NLR,  and  other  laboratory  data  of
he  patients  were  recorded  for  all  groups.  The  correlations
etween  the  MPV  and  NLR  were  evaluated  in  the  SHL  group
nd  in  the  control  group,  and  SHL  patients  were  compared
ccording  to  the  recovery  and  severity  of  hearing  loss.  Also,
orrelation  between  the  MPV  and  NLR  was  determined  in  the
HL  patient  group.
The  study  was  approved  by  the  local  ethics  committee
nd  conducted  in  accordance  with  the  ethical  principles
escribed  by  the  Declaration  of  Helsinki.  An  informed  con-
ent  was  obtained  from  all  participants  prior  to  their
articipation  in  the  study.
SPSS  for  Windows,  version  15.0,  software  was  used  for
ll  data  analyses.  Data  distributions  were  analyzed  with  the
hapiro--Wilk  test.  Student’s  t-test  for  independent  sam-
les  was  used  to  analyze  age,  MPV  values,  and  platelet
ount.  In  cases  of  normal  distribution,  Mann--Whitney’s  U
est  was  used  to  compare  the  groups  (gender).  The  cor-
elations  between  the  variable  pairs  were  analyzed  using
earson’s  correlation  test.  A  level  of  p  <  0.05  was  considered
igniﬁcant.
esults
here  was  no  signiﬁcant  difference  between  the  age  or  gen-
er  in  the  SHL  and  control  groups.  The  mean  age  of  patients
nd  controls  were  46.10  ±  11.91  and  42.84  ±  11.85  years,
espectively.  The  male-to-female  ratio  in  the  SHL  group  was
8:21,  and  31:28  in  the  control  group  (Table  1).
The  laboratory  data  of  patients  and  controls  are  shown
n  Table  1.  The  mean  MPV  value  was  9.83  ±  1.50  fL  in  the
atients  and  9.98  ±  0.07  fL  in  the  control  group,  and  the
ifference  was  not  statistically  signiﬁcant  (p  =  0.470).  The
ean  NLR  value  was  3.24  ±  2.26  in  the  SHL  patients  and
.53  ±  0.47  in  the  control  group,  and  the  difference  was
tatistically  signiﬁcant  (p  =  0.001;  Table  1).
ume  (MPV),  neutrophil-to-lymphocyte  ratio  (NLR)  values,  and
Control  (n  =  59)
Mean  ±  SD
p-Value
42.84  ±  11.85  0.140
0.193
28  (47.5%)
31  (52.5%)
1.53  ±  0.47  0.001a
9.98  ±  0.07  0.470
244.86  ±  47.25  0.603
6.29  ±  0.973  0.001a
3.43  ±  0.71  0.001a
2.35  ±  0.53  0.029a
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The  laboratory  data  of  the  SHL  group  according  to
response  to  the  treatment  as  recovered  and  unrecovered
groups  are  shown  in  Table  2.  The  mean  MPV  value  was
9.91  ±  1.49  fL  in  the  unrecovered  group  and  9.75  ±  1.52  fL
in  the  recovered  group,  and  the  difference  was  not  sta-
tistically  signiﬁcant  (p  =  0.785).  The  mean  NLR  value  was
4.45  ±  2.63  in  the  unrecovered  group  and  2.15  ±  1.04  in  the
recovered  group,  and  the  difference  was  statistically  signif-
icant  (p  =  0.001;  Table  2).
The  mean  NLR  and  MPV  values  according  to  severity  of
hearing  loss  are  shown  in  Table  3.  A  statistically  signiﬁcant
correlation  was  observed  between  NLR  values  and  sever-
ity  of  hearing  loss  (p  =  0.015).  The  mean  NLR  values  in  the
patients  with  severe  SHL  were  signiﬁcantly  higher  than  in
the  mild  SHL  group  (p  =  0.004).  However,  there  was  no  cor-
relation  between  MPV  values  and  severity  of  hearing  loss
(p  =  0.701).
No  correlation  was  observed  between  MPV  and  NLR  in  the
SHL  group  (r  =  0.190;  p  =  0.149).
Discussion
The  key  to  successful  treatment  of  diseases  lies  in  the
understanding  of  their  etiopathogenesis.  Since  the  phys-
iopathology  of  SHL  is  still  unclear,  there  are  conﬂicting
theories  regarding  its  true  cause.8,23,24 There  are  many  theo-
ries  as  to  the  origin  of  this  disease,  including  viral  infections,
inﬂammation,  blood  disorders,  vascular  causes,  immune
disorders,  and  rupture  of  the  labyrinthine  membrane.12,25,26
Since  the  cochlea  is  mainly  supplied  by  a  single,  terminal
t
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h
p
Table  2  Comparison  of  laboratory  data  between  the  recovered  a
Variables  Unrecovered
(n  =  31)
Mean  ±  SD
NLR  4.45  ±  2.63  
MPV  (fL)  9.91  ±  1.49  
Platelet (103  U)  248.50  ±  48.69  
WBC (103  U)  9.20  ±  3.27  
Neutrophil (103  U)  6.76  ±  2.92  
Lymphocyte  (103  U)  1.80  ±  0.77  
SD, standard deviation; MPV, mean platelet volume; NLR, neutrophil-to
a p < 0.05.
Table  3  Mean  analysis  for  NLR  and  MPV  according  to  severity  o
severe (profound,  >80  dB).
1  Mild  (n  =  24)  2  Moderate  (n  =  2
Mean ±  SD  Mean  ±  SD  
MPV  (fL)  9.83  ±  1.58  9.74  ±  1.56  
NLR 2.35  ±  1.14  3.25  ±  2.06  
SD, standard deviation; MPV, mean platelet volume; NLR, neutrophil-to
a p < 0.05.den  hearing  loss  639
rtery  (the  labyrinthine  artery),  the  inner  ear  is  very  much
rone  to  circulatory  alterations.27 In  vascular  cases,  the
roblems  may  be  present  on  the  blood  vessel  wall,  as  is  the
ase  in  arteritis  and  spasms,  or  they  may  be  intravascular.
 history  of  vascular  disease  or  platelet  alterations  is  the
nly  clinical  ﬁnding  that  could  lead  one  to  infer  a  vascular
ause  of  SHL.  Although  the  most  widely  accused  factor  in
he  etiology  is  viral  inﬂammation  of  the  neural  ﬁbers  and
anglia,28 this  has  not  been  proven  yet.
NLR  is  an  easily  measured  biomarker  that  correlates
ith  clinical  status.  It  is  calculated  from  CBC,  and  is
n  inexpensive,  easy  to  obtain,  widely  available  marker
f  inﬂammation  that  can  aid  in  the  risk  stratiﬁcation  of
atients  with  various  diseases.1,13,29,30 It  is  as  valuable  as
ome  high-cost  inﬂammatory  markers,  including  IL-6,  IL-
,  IL-8,  and  TNF-.31 Conversely,  MPV  can  be  used  as
arker  for  high  platelet  activity,  which  takes  an  active
ole  in  the  pathophysiology  of  thrombosis,  coagulation,  and
therosclerosis.32
In  recent  studies,  NLR  was  determined  to  be  a  reliable
arker  for  the  diagnosis  and  prediction  of  the  SHL  and  Bell’s
alsy  prognoses.14,15,33 Ulu  et  al.  reported  that  when  the
atients  with  SHL  were  compared  according  to  the  recovery,
LR  levels  were  higher  in  patients  who  did  not  recover.  This
ay  be  explained  with  the  higher  inﬂammatory  situation
n  unrecovered  patients,  and  this  result  may  help  clinicians
aring  for  SHL  patients  with  higher  NLR  levels  in  terms  of
reatment  and  prognosis.15 In  the  previous  study  by  Masuda
t  al.,  neutrophil  and  levels  of  inﬂammatory  markers  were
igher  in  SHL  patients.34 Most  recently,  Ozler  classiﬁed  SHL
atients  according  to  severity  of  hearing  loss  as  mild  (<40  dB
nd  unrecovered  patients.
Recovered  (n  =  28)
Mean  ±  SD
p-Value
2.15  ±  1.04  0.001a
9.75  ±  1.52  0.785
250.86  ±  48.47  0.767
7.67  ±  2.16  0.118
4.64  ±  1.65  0.006a
2.30  ±  0.70  0.012a
-lymphocyte ratio; WBC, white blood cell.
f  hearing  loss  as  mild  (<40  dB),  moderate  (up  to  80  dB),  and
4)  3  Severe  (n  =  11)  p
Mean  ±  SD
10.00  ±  1.27  0.701
5.15  ±  3.33  0.015a
1--2,  p  =  0.117
2--3,  p  =  0.092
1--3,  p  =  0.004a
-lymphocyte ratio.
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140  
oss  for  any  frequency),  moderate  (up  to  80  dB),  and  severe
>80  dB),  and  found  that  the  mean  NLR  values  in  patients
ith  SHL  were  signiﬁcantly  higher  than  in  the  control  group,
nd  that  the  mean  NLR  values  in  patients  with  severe  sen-
orineural  hearing  loss  were  signiﬁcantly  higher  than  in  the
ther  groups.35 In  the  present  study,  NLR  values  were  sig-
iﬁcantly  higher  in  patients  with  SHL  when  compared  with
he  control  group.  Similarly,  the  mean  NLR  was  higher  in  the
nrecovered  patients  when  compared  with  those  who  recov-
red;  a  signiﬁcant  correlation  was  observed  between  NLR
alues  and  severity  of  hearing  loss,  indicating  the  presence
f  inﬂammation.
Platelets  play  an  active  role  in  the  pathophys-
ology  of  thrombosis,  coagulation,  inﬂammation,  and
therosclerosis.9,36 Upon  activation,  platelets  release
asoactive  and  thrombogenic  agents,  which  are  important
actors  in  the  formation  of  thrombosis  in  the  vessel.  Sev-
ral  investigators  have  used  a  series  of  platelet  indices  that
re  measured  by  hematology  analyzers,  since  platelet  acti-
ation  leads  to  morphologic  changes.37 Large  platelets  are
etabolically  and  enzymatically  more  active  and  have  a
igher  thrombotic  potential.38 Higher  MPV  values  are  ben-
ﬁcial  markers  of  higher  platelet  activity  and  were  found
o  be  associated  with  atherothrombosis.  In  addition,  MPV
s  one  of  the  most  extensively  studied  platelet  activation
arkers.32,39
MPV  values  were  studied  in  patients  with  SHL,  yielding
ontroversial  results.  In  the  recent  studies  by  Ulu  et  al.
with  40  patients  and  controls)  and  by  Sagit  et  al.  (with
1  patients  and  controls),  the  mean  MPV  values  in  SHL
atients  were  10.5  ±  0.9  fL  and  9.01  ±  1.24  fL,  respectively,
hich  were  signiﬁcantly  higher  than  the  values  of  the  control
roups  (9.6  ±  0.5  fL  and  8.21  ±  0.76  fL,  respectively).20,21 In
nother  study  by  Karli  et  al.  (with  46  patients  and  con-
rols),  the  mean  MPV  value  was  8.25  ±  0.86  fL  in  SHL  patients
nd  7.98  ±  0.87  fL  in  the  control  group,  which  was  not  sig-
iﬁcantly  different,  and  they  concluded  that  there  was
o  microvascular  response  in  the  etiology  of  SHL.19 In  the
resent  study  (with  59  patients  and  controls),  the  mean  MPV
alue  was  9.83  ±  1.50  fL  in  SHL  patients  and  9.98  ±  0.07  fL
n  the  control  group;  similarly,  the  mean  MPV  value  was
.91  ±  1.49  fL  in  the  unrecovered  group,  and  9.75  ±  1.52  fL
n  the  recovered  group,  and  there  was  no  signiﬁcantly  dif-
erence  between  the  groups.  The  absence  of  any  correlation
f  MPV  with  any  of  the  studied  parameters  may  suggest  that
icrovascular  response  is  a  suspicious  theory  in  etiopatho-
enesis  of  SHL.
In  a  large  epidemiologic  study  with  326  patients  by
emirin  et  al.,  the  mean  MPV  value  in  normal  Turkish  adults
as  8.9  ±  1.4  fL,  and  95%  of  the  individuals  had  an  MPV
etween  7.2  and  11.7  fL.40 If  the  MPV  values  of  the  con-
rol  group  in  this  study  were  equivalent  to  those  of  the
tudy  by  Demirin  et  al.,  the  present  results  would  have  been
onsidered  signiﬁcant.
onclusionhe  results  of  the  present  study  indicated  that,  when  the
HL  patients  were  compared  according  to  the  recovery,  NLR
evels  were  higher  in  patients  who  did  not  recover.  However,
o  such  correlation  was  observed  between  MPV  levels  and
1Kum  RO  et  al.
atient  recovery.  This  may  indicate  that  inﬂammation  plays
 larger  role  in  the  pathogenesis  of  SHL  than  the  microvas-
ular  response.  In  the  evaluation  of  SHL,  NLR  is  a  quick
nd  reliable  marker  for  predicting  the  diagnosis  and  prog-
osis,  while  MPV  may  be  a  less  important  marker.  Although
he  present  sample  size  was  larger  than  that  used  in  pre-
ious  studies,  this  issue  should  be  investigated  in  a  larger
atient  cohort.  Because  this  area  of  research  is  a  novel  ﬁeld,
rospective,  multicenter,  controlled  studies  are  needed.
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